Business Description
Aldeyra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US01438T1060
Description
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.7 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.44 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17.5 | |||||
| 3-Year EPS without NRI Growth Rate | 15.5 | |||||
| 3-Year FCF Growth Rate | 22.5 | |||||
| 3-Year Book Growth Rate | 9.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.6 | |||||
| 9-Day RSI | 60.05 | |||||
| 14-Day RSI | 56.67 | |||||
| 6-1 Month Momentum % | 33.6 | |||||
| 12-1 Month Momentum % | 122.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | |||||
| Quick Ratio | 4.55 | |||||
| Cash Ratio | 4.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.3 | |||||
| Shareholder Yield % | 0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -32.4 | |||||
| ROA % | -26.35 | |||||
| ROIC % | -231.27 | |||||
| 3-Year ROIIC % | -63.53 | |||||
| ROC (Joel Greenblatt) % | -5669.25 | |||||
| ROCE % | -29.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.88 | |||||
| Price-to-Tangible-Book | 2.87 | |||||
| EV-to-EBIT | -4.97 | |||||
| EV-to-Forward-EBIT | -1.79 | |||||
| EV-to-EBITDA | -5.01 | |||||
| EV-to-Forward-Revenue | 17.1 | |||||
| EV-to-FCF | -5.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.89 | |||||
| Price-to-Net-Cash | 3.06 | |||||
| Earnings Yield (Greenblatt) % | -20.12 | |||||
| FCF Yield % | -10.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aldeyra Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.593 | ||
| Beta | 1.09 | ||
| Volatility % | 91.35 | ||
| 14-Day RSI | 56.67 | ||
| 14-Day ATR (€) | 0.158873 | ||
| 20-Day SMA (€) | 5.02555 | ||
| 12-1 Month Momentum % | 122.58 | ||
| 52-Week Range (€) | 2.216 - 5.696 | ||
| Shares Outstanding (Mil) | 59.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aldeyra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aldeyra Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aldeyra Therapeutics Inc Frequently Asked Questions
What is Aldeyra Therapeutics Inc(STU:137)'s stock price today?
The current price of STU:137 is €5.20. The 52 week high of STU:137 is €5.70 and 52 week low is €2.22.
When is next earnings date of Aldeyra Therapeutics Inc(STU:137)?
The next earnings date of Aldeyra Therapeutics Inc(STU:137) is 2025-02-07 Est..
Does Aldeyra Therapeutics Inc(STU:137) pay dividends? If so, how much?
Aldeyra Therapeutics Inc(STU:137) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers